Drugs / Lovastatin
Lovastatin
also known as
Mevacor · 6.alpha.-methylcompactin · Altoprev · C10AA02 · L-154803 · LOV · Lovastatin component of advicor · Lovastatina · +13 more
Small molecule targets CAV1, HMGCR, MYC via inhibition
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | MEVACOR | — | 1991-03-28 – 2005-04-07 | fda.gov ↗ |
| Label expansion | US (FDA) | ALTOPREV | — | 2002-09-11 | fda.gov ↗ |
| Approved | US (FDA) | MEVACOR | — | 1987-08-31 | fda.gov ↗ |
Trials 47 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 14 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02603770 Comparator | Nov 2015 → Jan 2016 | inherited lipid metabolism disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00352599 Comparator | Sep 2009 → Mar 2014 | neurofibromatosis type 1 | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00689806 Comparator | — | chronic asthma | University of Chicago | Withdrawn | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03763175 Comparator | Dec 2018 → Oct 2020 | irritable bowel syndrome | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03981601 Comparator | Feb 2018 → Mar 2019 | bone resorption disease | Islamic Azad University, Sanandaj | Unknown | No outcome recorded |
| Phase 2 | NCT02964884 Comparator | Nov 2016 → Jan 2027 expected | neurofibromatosis type 1, reading disorder | Vanderbilt University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01890967 Background | Jun 2013 → Apr 2014 | hyperlipoproteinemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01976936 Comparator | Feb 2009 → Nov 2015 | hyperbilirubinemia, ischemic stroke, myopathy | Columbia University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03178526 Comparator | Dec 2015 → Jan 2016 | chronic periodontitis | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT03510715 Background | Aug 2018 → Feb 2020 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03510884 Background | May 2018 → Jan 2021 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00532311 Comparator | Jul 2007 → Apr 2008 | hyperlipidemia | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00092846 Background | Dec 2002 → Sep 2003 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02642653 Comparator | Jan 2016 → Jul 2018 | fragile X syndrome | University of California, Davis | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2001-12-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval of Lovastatin Tablets tevapharm.com ↗ |
| 2001-06-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Lovastatin Tablets tevapharm.com ↗ |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 64 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lovastatin | “Healthy subjects were randomly allocated to receive a single dose of either four 600 mg red yeast rice capsules or one 20 mg lovastatin tablet; after 7-day washout period, they...” NCT01346670 ↗59“The purpose of this study is to determine whether short-term use of the drugs ibuprofen and lovastatin affects levels of a protein called beta-amyloid in people who are at risk...” NCT00046358 ↗ “Statins include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin, rosuvastatin and simvastatin.” NCT06553157 ↗ “SYN-010 is a modified release, oral formulation of lovastatin being developed for the treatment of IBS-C.” NCT03763175 ↗ “lovastatin” NCT01890967 ↗ |
| Known as | 6.alpha.-methylcompactin | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | Altoprev | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | C10AA02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | L-154803 | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | LOV | “In animal studies, pathway-specific pharmacological interventions with lovastatin (LOV) and lamotrigine (LTG) have been shown to improve synaptic plasticity as well as...” PMID 37280688 ↗ Jun 2023 |
| Known as | Lovastatin component of advicor | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | Lovastatina | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | Lovastatine | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | Mevacor | “Both Niaspan and lovastatin (Mevacor®) are approved by the United States Food and Drug Administration (FDA) to treat high cholesterol.” NCT00071266 ↗1“Mevacor” NCT00532311 ↗ |
| Known as | Mevinacor | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | Mevinacor 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | Mevinacor 40 | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | Mevinolin | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | Mevlor | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | MK-803 | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | MK0803 | “MK0803, lovastatin” NCT00092846 ↗ |
| Known as | Monacolin k | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | NSC-758662 | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | Simvastatin impurity, lovastatin- | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | Sivlor | ChEMBL registry synonym — accepted as the source's own label CHEMBL503 ↗ |
| Known as | SYN-010 | “SYN-010 is a modified release, oral formulation of lovastatin being developed for the treatment of IBS-C.” NCT03763175 ↗ |
| Action | Inhibit | “inhibits 3-hydroxy, 3-methyl glutaryl coenzyme A reductase” NCT00000469 ↗ |
| Modality | Small molecule | “hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins)” PMID 19574441 ↗ Jul 2009 |
| Route | Oral | “Lovastatin 80 mg/day as 40 mg orally twice daily.” NCT00285857 ↗ |
| Target | HMGCR | “hydroxymethylglutaryl-coenzyme A reductase inhibitors” PMID 19574441 ↗ Jul 2009 |